Signature of a silent killer: expression profiling in epithelial ovarian cancer.
With the sequencing of the human genome and the simultaneous development of high-throughput strategies, cancer biologists have entered an exciting new area for gene expression analysis, with the ability to glimpse higher order patterns of genetic and epigenetic alterations in complex diseases. Ovarian cancer biologists are rising to the challenge of applying these new technologies to this silent killer, with the eventual goal of improving the quality of life and long-term survival of patients. This review provides a summary of the disease, a description of available technologies and their application to the ovarian cancer problem, as well as a discussion on the challenges and opportunities related to DNA microarray expression profiling-based research, including downstream clinical applications.
Le Page
Cécile
C
Centre de recherche du Centre Hospitalier de l'Université de Montréal/Institut du cancer de Montréal, 1560, rue Sherbrooke est, Montréal, Quebec H2L 4M1, Canada. cecilelepage@yahoo.ca
Provencher
Diane
D
Maugard
Christine M
CM
Ouellet
Véronique
V
Mes-Masson
Anne-Marie
AM
D014408:Biomarkers, Tumor; D004847:Epithelial Cells / Q000473:pathology / Q000502:physiology*; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
D014408:Biomarkers, Tumor